Slxn stock forecast sentiment remains constructive

SLXN stock forecast sentiment remains constructive, with options market data revealing increased call volume at strike prices above $15, signaling trader optimism into Q Bad Bunny Used His Saturday Night Live Gig to Roast MAGA On July 9, 2025, Silexion Therapeutics announced positive preclinical results for SIL204, demonstrating significant efficacy in human lung cancer cell lines. The study highlighted SIL204’s potential as a versatile therapeutic for KRAS-driven cancers, supporting its innovative lipid-conjugated delivery system. The company is preparing for a Phase 2/3 clinical trial in 2026 and is conducting additional studies on a new KRAS mutation, which could establish SIL204 as a potential pan-KRAS treatment. On the valuation front, SLXN stock forecast shows forward PEG ratio near 1.4, which is appealing compared to historical norms, possibly drawing value-focused funds back into the name.